• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

beta-Lactamase inhibitors and the inducibility of the beta-lactamase of Mycobacterium tuberculosis.

作者信息

Zhang Y, Steingrube V A, Wallace R J

机构信息

Department of Microbiology, University of Texas Health Center, Tyler 75710.

出版信息

Am Rev Respir Dis. 1992 Mar;145(3):657-60. doi: 10.1164/ajrccm/145.3.657.

DOI:10.1164/ajrccm/145.3.657
PMID:1546847
Abstract

Ten clinical isolates and the type strain (H37Rv) of Mycobacterium tuberculosis were shown to produce an intracellular beta-lactamase. Crude enzyme preparations were extracted from acetone cell powders by grinding with zirconium beads in 0.133 M glycine with 1.0% Triton X-100. The enzymes had identical patterns on isoelectric focusing, with two major bands at isoelectric points of 4.9 and 5.1. The beta-lactamase was highly susceptible to the new beta-lactamase inhibitor BRL 42715, with an I50 of 0.0001 microgram/ml. The enzyme was also susceptible to clavulanic acid with an I50 (0.05 microgram/ml), which was similar to the value for the common bacterial beta-lactamase TEM-1 (0.01 microgram/ml). The latter result is consistent with previous MIC studies with M. tuberculosis, which have shown synergy between clavulanic acid and amoxicillin. BRL 42715 and clavulanic acid were more active than sulbactam, tazobactam, and cloxacillin. These studies support the potential value of penicillin/clavulanic acid and penicillin/BRL 42715 combinations in the treatment of tuberculosis.

摘要

相似文献

1
beta-Lactamase inhibitors and the inducibility of the beta-lactamase of Mycobacterium tuberculosis.
Am Rev Respir Dis. 1992 Mar;145(3):657-60. doi: 10.1164/ajrccm/145.3.657.
2
[A study of beta-lactamase activity of mycobacteria and clinical trial of penicillin/beta-lactamase inhibitor combinations in the treatment of drug-resistant Mycobacterium tuberculosis].
Kekkaku. 1999 May;74(5):447-52.
3
Characterization of beta-lactamases in Mycobacterium fortuitum including a role in beta-lactam resistance and evidence of partial inducibility.偶然分枝杆菌中β-内酰胺酶的特性,包括其在β-内酰胺耐药性中的作用及部分诱导性的证据
Am Rev Respir Dis. 1986 Dec;134(6):1276-82. doi: 10.1164/arrd.1986.134.5.1276.
4
The vitro efficacy of beta-lactam and beta-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis.β-内酰胺类与β-内酰胺酶抑制剂对耐多药结核分枝杆菌临床菌株的体外疗效
Int J Antimicrob Agents. 2004 Apr;23(4):408-11. doi: 10.1016/j.ijantimicag.2003.09.023.
5
Partial characterization of Nocardia farcinica beta-lactamases.豚鼠诺卡氏菌β-内酰胺酶的部分特性分析
Antimicrob Agents Chemother. 1993 Sep;37(9):1850-5. doi: 10.1128/AAC.37.9.1850.
6
beta-Lactamase activity in mycobacteria including Mycobacterium avium and suppression of their growth by a beta-lactamase-stable antibiotic.分枝杆菌(包括鸟分枝杆菌)中的β-内酰胺酶活性以及一种β-内酰胺酶稳定型抗生素对其生长的抑制作用。
Microbios. 1995;81(328):177-85.
7
The effects of clavulanic acid and sulbactam on beta-lactamase biosynthesis.
J Antimicrob Chemother. 1988 Aug;22(2):105-11. doi: 10.1093/jac/22.2.105.
8
Evolution of beta-lactamase inhibitors.
Pharmacotherapy. 1991;11(2 ( Pt 2)):37S-39S.
9
[Identification of a cephalosporinase susceptible to clavulanic acid in a clinical strain of Serratia fonticola].
Pathol Biol (Paris). 1995 Apr;43(4):315-9.
10
Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae.志贺菌中克服超广谱β-内酰胺酶(ESBLs)和 AmpC β-内酰胺酶的策略。
Int J Antimicrob Agents. 2011 May;37(5):405-9. doi: 10.1016/j.ijantimicag.2010.11.028. Epub 2011 Jan 26.

引用本文的文献

1
Stabilization of Tuberculosis Reporter Enzyme Fluorescence (REFtb) Diagnostic Reagents for Use at the Point of Care.用于即时检测的结核报告酶荧光(REFtb)诊断试剂的稳定性
Diagnostics (Basel). 2022 Jul 19;12(7):1745. doi: 10.3390/diagnostics12071745.
2
Morphological profiling of tubercle bacilli identifies drug pathways of action.结核分枝杆菌形态分析鉴定药物作用途径。
Proc Natl Acad Sci U S A. 2020 Aug 4;117(31):18744-18753. doi: 10.1073/pnas.2002738117. Epub 2020 Jul 17.
3
Rapid Tuberculosis Diagnosis Using Reporter Enzyme Fluorescence.
利用报告酶荧光快速诊断结核病。
J Clin Microbiol. 2019 Nov 22;57(12). doi: 10.1128/JCM.01462-19. Print 2019 Dec.
4
Activity of the New β-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with β-Lactams against Mycobacterium abscessus Complex Clinical Isolates.新型β-内酰胺酶抑制剂雷利巴坦和沃巴坦与β-内酰胺类药物联合对脓肿分枝杆菌复合体临床分离株的活性。
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02623-18. Print 2019 Mar.
5
Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.美罗培南-克拉维酸对多重耐药结核分枝杆菌具有较高的体外活性。
Antimicrob Agents Chemother. 2015;59(6):3630-2. doi: 10.1128/AAC.00171-15. Epub 2015 Mar 30.
6
C4-alkylthiols with activity against Moraxella catarrhalis and Mycobacterium tuberculosis.具有抗卡他莫拉菌和结核分枝杆菌活性的 C4- 硫醇。
Bioorg Med Chem. 2011 Nov 15;19(22):6842-52. doi: 10.1016/j.bmc.2011.09.030. Epub 2011 Oct 1.
7
Imaging tuberculosis with endogenous beta-lactamase reporter enzyme fluorescence in live mice.利用内源性β-内酰胺酶报告酶荧光在活鼠中成像结核分枝杆菌。
Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12239-44. doi: 10.1073/pnas.1000643107. Epub 2010 Jun 21.
8
Morphological features and signature gene response elicited by inactivation of FtsI in Mycobacterium tuberculosis.结核分枝杆菌中FtsI失活引发的形态学特征和标志性基因反应。
J Antimicrob Chemother. 2009 Mar;63(3):451-7. doi: 10.1093/jac/dkn507. Epub 2008 Dec 24.
9
Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics.结核分枝杆菌β-内酰胺酶的晶体结构与活性研究揭示了其在对β-内酰胺类抗生素耐药性中的关键作用。
Antimicrob Agents Chemother. 2006 Aug;50(8):2762-71. doi: 10.1128/AAC.00320-06.
10
Pharmacokinetic factors in the modern drug treatment of tuberculosis.结核病现代药物治疗中的药代动力学因素
Clin Pharmacokinet. 1999 Aug;37(2):127-46. doi: 10.2165/00003088-199937020-00003.